BioSpace News Archive

Agenus (NASDAQ: AGEN) today announced that it will release its third quarter 2021 financial results before the market opens on Tuesday, November 9, 2021.

Tremeau Pharmaceuticals today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/240,446. Once issued, the patent will provide composition of matter patent protection for Tremeau’s novel deuterium-enriched etoricoxib compound, TRM-362 (d3-etoricoxib), through at least April 2041.

Nereid Therapeutics, a company discovering new disease treatments by applying pioneering research and technologies in biomolecular condensates, announces the appointment of Laura L. Forese, M.D., MPH, and Rupert Vessey, FRCP, Ph.D., to its Board of Directors.

iTolerance, Inc. announced the appointments of and Dennis M. Hester, Ph.D., Senior Vice President of Chemistry, Manufacturing and Controls, effective July 2021, and Sumitra M. Ghate, Vice President, Regulatory Affairs, effective October 2021, to the Company’s executive leadership team.

Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), today announced that it will host a key opinion leader (KOL) webinar on the compelling need to salvage central venous catheters in patients with central line associated blood stream infections (CLABSI) on Thursday, November 11, 2021 at 11:30am Eastern Time.

Melinta Therapeutics, LLC (“Melinta”), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announces the appointment of Dr. Doug Girgenti as Vice President of Drug Development, effective today.

Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of stem cell-based delivery of oncolytic viruses, announced today its selection as a finalist for presentation during the Innovation Showcase at the upcoming sixth annual Oncolytic Virotherapy Summit.

Inspiritol, Inc., a virtual pharmaceutical start-up filed a response with the FDA as part of their Investigational New Drug Application process for Inspiritol, a novel treatment for COVID-19, Long-COVID, and ME/CFS (Myalgic encephalomyelitis/chronic fatigue).

EnPro Industries, Inc. (NYSE: NPO) intends to release financial results for the third quarter of 2021 on Friday, November 5, 2021, before the opening of trading on the New York Stock Exchange.

MedinCell will be attending the 12th Jefferies London Healthcare Conference on Tuesday, November 16 and Wednesday, November 17 at the Waldorf Hilton in London.